Skip to main content
Figure 1 | Alzheimer's Research & Therapy

Figure 1

From: A phase Ib multiple ascending dose study of the safety, tolerability, and central nervous system availability of AZD0530 (saracatinib) in Alzheimer’s disease

Figure 1

AZD0530 in human cerebrospinal fluid at different doses. (A) Each point represents fasting trough cerebrospinal fluid (CSF) AZD0530 level from a different human subject for the left three columns. The mouse trough CSF values are derived from brain levels at the 5 mg/kg per day dose that rescued memory deficits [43]. ** P < 0.001, one-way analysis of variance with Tukey post-hoc comparisons. (B) Relationship between CSF and plasma AZD0530 levels. Each point is from a different individual, and different dose groups are illustrated with different colors. There is a tight correlation of plasma and CSF level as indicated (R2 = 0.97, Pearson correlation coefficient). Bars represent mean ± standard error of the mean. n.s, Not significant.

Back to article page